|PRXL -- USA Stock|| |
USD 88.06 0.04 0.0454%
Ms. Ellen M. Zane is an Independent Director of Parexel International Corporationrationration. She is Chairman of the Compensation Committee and a member of the Human Resources Committee. Since September 2011, Ms. Zane has served as CEO Emeritus and Vice Chair, Board of Trustees of Tufts Medical Center, an academic medical center that is the principal teaching hospital for Tufts University School of Medicine in Boston, Massachusetts. From January 2004 to September 2011, she served as President and Chief Executive Officer of Tufts Medical Center. From May 1994 to January 2004, she served as Network President for Partners Healthcare System, a physician and hospital network founded by the Harvard affiliated Massachusetts General Hospital and Brigham and Womens Hospital. Prior to 2004, Ms. Zane served as Chief Executive Officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane currently serves on the boards of directors of Boston Scientific Corporationrationration, Brooks Automation, Inc., Press Ganey Holdings, Inc., Century Capital Management Inc., and Fiduciary Trust Company.
Age: 64 CEO Since 2006
781 487-9900 http://www.parexel.com
Zane currently serves on the boards of directors of Brooks Automation, Inc., Haemonetics Corporationrationrationration, Press Ganey Holdings, Inc., Century Capital Management Inc., and Fiduciary Trust Company. We believe Ms. Zane?s experience of over 30 years in management of large academic medical centers/hospitals and community health care related enterprises, including 21 years as an executive, is valuable to our Board and the Company.
Ellen Zane Latest Insider Activity
The company has return on total asset (ROA)
of 6.72 %
which means that it generated profit of $6.72 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE)
of 16.93 %
meaning that it created $16.93 on every $100 dollars invested by stockholders.
The company currently holds 671.5M in liabilities with Debt to Equity (D/E)
ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio
of 1.42 which is within standard range for the sector.
PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corporation (PRXL) is traded on NASDAQ in USA and employs 18,600 people.
PAREXEL International Leadership Team
|Michelle Graham, Chief Human Resource Officer, Senior Vice President|
|Ulf Schneider, Chief Administrative Officer, Senior Vice President|
|Thomas Senderovitz, Senior Vice President - Clinical Research Services|
|Dana Callow, Presiding Independent Director|
|Emma Reeve, Interim CFO, Corporate Vice President Controller|
|Josef Rickenbach, Founder, Chairman and CEO|
|Patrick Fortune, Independent Director|
|Eduard Holdener, Independent Director|
|Simon Harford, CFO, Senior Vice President|
|Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access|
|Gadi Saarony, Senior Vice President - Clinical Research Services|
|Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center|
|Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting|
|Xavier Flinois, President - Perceptive Informatics|
|Douglas Batt, Sr. VP, General Counsel and Secretary|
|Sybrand Pretorius, Senior Vice President Chief Scientific Officer|
|Maykin Ho, Director|
|Richard Love, Independent Director|
|Ronald Aldridge, Sr. Director, Investor Relations|
|Mark Goldberg, President COO|
|Roland Andersson, Senior Vice President - Clinical Research Services|
|Christopher Lindop, Independent Director|
|Ingo Bank, CFO and Sr. VP|
|David Godwin, Senior Vice President-Global Business|
Stock Performance Indicators
Most of Macroaxis users are at this time bullish on PAREXEL International Corporation. What is your perspective on investing in PAREXEL International Corporation? Are you bullish or bearish?
Currently Active Assets on Macroaxis
Additionally take a look at Your Equity Center
. Please also try Positions Ratings
module to determine portfolio positions ratings based on digital equity recommendations. macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.